T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis.
Immunity
View this publicationImmunity
View this publicationScientific reports
View this publicationCell reports
View this publicationSeminars in cancer biology
View this publicationJournal of immunology (Baltimore, Md. : 1950)
View this publicationFrontiers in immunology
View this publicationEuropean journal of cancer (Oxford, England : 1990)
View this publicationJournal for immunotherapy of cancer
View this publicationCancer immunology research
View this publicationClinical & translational immunology
View this publication